Figures & data
Table 1 Demographics and clinical characteristics of COPD patients in the two phenotypes
Figure 1 (A) The spectrum shows a wide range of metabolites. Representative 1H-NMR spectrum of plasma samples obtained from (B) phenotype E pretreatment, (C) phenotype E posttreatment, (D) phenotype M pretreatment and (E) phenotype M posttreatment.
![Figure 1 (A) The spectrum shows a wide range of metabolites. Representative 1H-NMR spectrum of plasma samples obtained from (B) phenotype E pretreatment, (C) phenotype E posttreatment, (D) phenotype M pretreatment and (E) phenotype M posttreatment.](/cms/asset/8f6977bb-c4ea-457f-945e-7da5a5444d85/dcop_a_152134_f0001_c.jpg)
Figure 2 PCA (A–D) and PLS-DA (E–H) score plots demonstrated good separation between different groups.
Abbreviations: EH, phenotype E posttreatment; EQ, phenotype E pretreatment; MH, phenotype M posttreatment; MQ, phenotype M pretreatment; PCA, principal component analysis; PLS-DA, partial least squares discriminant analysis.
![Figure 2 PCA (A–D) and PLS-DA (E–H) score plots demonstrated good separation between different groups.](/cms/asset/ed30eb55-b166-4c46-83fb-0c79e3580dc6/dcop_a_152134_f0002_c.jpg)
Table 2 Summary of the parameters for assessing the quality of the PLS-DA model
Table 3 Quantitative comparison and the relative integrals of metabolites in the EQ, MQ, EH and MH groups